Navigation Links
NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
Date:1/17/2008

WALDWICK, N.J., Jan. 17 /PRNewswire-FirstCall/ -- NEXCORE Technology, Inc, a world-class original equipment manufacturer (OEM) of medical devices, has licensed all the intellectual property rights for the development of a major advance in fluid management during endoscopic surgery. The new system provides significantly greater control over the inflow/outflow of fluids during a procedure.

The patents on the system are held by Drs. Atul and Alka Kumar. Dr. Atul Kumar, a pioneer in hysteroscopic surgery, is scientific director of the Women's Health Center in Jaipur, India. Dr. Alka Kumar is the director of the Women's Health Center.

NEXCORE is designing and developing the new system and will organize testing and FDA approval.

According to Milton Frank, President and CEO of NEXCORE, "The new system maintains a constant preset cavity pressure during operations regardless of how the flow rate of the irrigational fluid is varied allowing for optimal visualization. The system measures the intravasation rate and total fluid intravasation."

Intravasation is fluid that is absorbed into the blood vessels during a procedure, which can cause severe injury, or even death, if not properly monitored.

The new system can be used in any endoscopic surgery. It distends the body tissue cavity by utilizing continuous flow irrigation. The new invention increases surgical efficiency, effectiveness and safety by maintaining a constant pressure on the mechanical distension of the cavity and increases and maintains visibility for the surgeon.
Features unique to the new system include:

-- The fluid pressure is independent of the flow rate and the desired

cavity pressure and distention can be maintained for an indefinite

time. A clinical study published in 2004 reported that endometrial

resections were performed on 539 women using the new system without any

complications because of the system's predictably stable mechanical

distention.

-- Predictably constant and clear visualization is present throughout the

procedure. Only negligible or minimal fluid turbulence is present

inside the cavity even at relatively high flow rates.

-- The real-time rate of intravasation is known throughout the procedure

thwarting fluid intravasation, or fluid overload, a dangerous

complication in procedures such as trans urethral surgery and

hysteroscopic surgery. In current systems, the fluid absorbed in the

patient's body is determined by subtracting the waste fluid from the

sterile fluid. In the new system, the instantaneous introduction of

fluid into the blood stream can be determined without any fluid sensors

and the surgeon can act within seconds.

-- It is possible to safely, easily and quickly switch between two

different types of irrigation fluid.

NEXCORE plans to introduce the system in late 2008.

NEXCORE Technology is a world-class OEM medical device manufacturer specializing in complex diagnostic and therapeutic systems. It produces some of the industries most innovative products for numerous large and sophisticated medical device manufacturers, taking the specifications from concept through design and manufacturing to after-market services. For additional company information: http://www.nexcoretech.com

Contact: Judd Cohen

Cohen Communications

212-682-7838

judd@cohencom.net


'/>"/>
SOURCE NEXCORE Technology, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solar energy technology licensed
2. Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons
3. Nanotechnology innovation may revolutionize gene detection in a single cell
4. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. BioSpace and the Massachusetts Biotechnology Council Launch 2008 Genetown(TM) Hotbed Campaign
6. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
7. NASA technology helps predict and prevent future pandemic outbreaks
8. National Nanotechnology Initiative releases new strategic plan
9. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
10. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
11. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016  According to ... next generation sequencing (NGS) market include significant efforts ... smaller sequencers.  More accessible and affordable sequencers, say ... growing demand for consumables including sample prep materials.  ... Market for Sample Preparation for Next Generation Sequencing ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):